Awards

$299K

Strain-Independent Therapeutic Antibodies for Influenza

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/14 - 06/30/15
PI: Lawrence Kauvar

DESCRIPTION (provided by applicant): Trellis Bioscience's CellSpot" technology for identification of rare human antibodies with high specificity and affinity against multiple antigen has enabled discovery of highly efficacious strain- independent antibodies to Respiratory Syncytial Virus and to Cytomegalovirus. We have now applied CellSpot to is...

$991K

Therapeutic Antibodies for CMV

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 02/01/14 - 01/31/15
PI: Lawrence Kauvar

DESCRIPTION (provided by applicant): Human cytomegalovirus (HCMV) is the major viral cause of birth defects and of medical complications associated with organ transplantation. Passive immunization using human immune globulin (HIG) has been shown to prevent disease. As pooled plasma, however, HIG is a variable product that potentially contains in...

$1MM

Therapeutic Antibodies for CMV

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 02/14/13 - 01/31/14
PI: William Robert Usinger

DESCRIPTION (provided by applicant): Human cytomegalovirus (HCMV) is the major viral cause of birth defects and of medical complications associated with organ transplantation. Passive immunization using human immune globulin (HIG) has been shown to prevent disease. As pooled plasma, however, HIG is a variable product that potentially contains in...

$300K

Therapeutic Antibodies for Rabies

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 09/01/12 - 08/31/13
PI: William Robert Usinger

DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot" technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody ...

$293K

Therapeutic Antibodies for Bacteria

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 09/01/12 - 08/31/13
PI: Lawrence Kauvar

DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot" technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody ...

$300K

Therapeutic Antibodies for CMV

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/01/12 - 01/31/13
PI: William Robert Usinger

DESCRIPTION (provided by applicant): Human cytomegalovirus (HCMV) is the major viral cause of birth defects and of medical complications associated with organ transplantation. Passive immunization using human immune globulin (HIG) has been shown to prevent disease. As pooled plasma, however, HIG is a variable product that potentially contains in...

$300K

Therapeutic Antibodies for Rabies

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 09/01/11 - 08/31/12
PI: William Robert Usinger

DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot" technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody ...

$300K

Therapeutic Antibodies for Bacteria

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 09/01/11 - 08/31/12
PI: Lawrence Kauvar

DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot" technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody ...

$250K

Multiplexed tissue staining in toxicological analysis

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 06/24/04 - 05/31/05
PI: Ellen J. Collarini

DESCRIPTION (provided by applicant): At present, the capacity for identifying candidate drugs exceeds the capacity for toxicological screening. If large panels of drug candidates could be rapidly and accurately screened in vitro for both activity and predicted toxicity, those with the best in vitro therapeutic index could be advanced for furt...

$137K

Multiplexed single cell cytokine secretion assay

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/15/04 - 12/14/04
PI: William D Harriman

DESCRIPTION (provided by applicant): Analysis of the cytokine network in normal immunoregulation and in disease processes has benefited from the development of the immunospot assay which can interrogate individual cells for secretion of specific immunoreactive antigens. In the ELISPOT version of this assay, cells are settled onto a solid phase s...

Load More